AI-generated analysis. Always verify with the original filing.
Tenaya Therapeutics, Inc. filed an 8-K on March 11, 2026, including a press release as Exhibit 99.1 under Item 2.02 (Results of Operations) and Item 9.01, which are not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. The filing discloses no specific financial results or operational details in the provided document content.
Event Type
Disclosure
Mandatory
Variant
8-K
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchang
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Tenaya Therapeutics, Inc., dated March 11, 2026 104 Cover Page In